Journal of cannabis research · 2025
Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lintzeris Nicholas, Arnold Jonathon C, McGregor Iain S, Mills Llewellyn
Аннотация
OBJECTIVES: To examine consumer perspectives regarding medicinal cannabis treatment provided to patients attending generalist health settings (GHS) compared to those attending medicinal cannabis clinics (MCC).
METHODS: An anonymous online survey, with convenience sampling of adults self-reporting prescribed medicinal cannabis in the preceding 12 months. Outcomes included participant characteristics, indications and patterns of cannabis use, consumer satisfaction.
RESULTS: Most participants (1899/2394, 79.3%) accessed treatment from MCC. Compared to generalist settings, MCC participants were younger (3.5 years, 95%CI: -4.7, -2.2), less likely to be prescribed oral products (OR = 0.4, 0.4-0.5), and had higher rates of employment (OR = 2.1, 1.8-2.5) and cannabis use disorder (OR = 1.5, 1.2-1.8). MCC participants were less likely to seek treatment for chronic pain (OR = 0.7, 0.6-0.8), but more likely for mental health conditions (OR = 1.6, 1.3-2.0). MCC participants had lower satisfaction levels regarding consultation duration (OR = 0.8, 0.7-0.9), information about potential harms and benefits (OR = 0.7, 0.6-0.9), use of other treatment approaches (OR = 0.5, 0.4-0.6) and treatment costs (OR = 0.6, 0.5-0.7).
CONCLUSION: We identified differences in the profile of patients, type of treatment provided between service settings, and there were higher levels of satisfaction amongst consumers accessing treatment in GHS settings. Further research is required to examine other dimensions of quality and appropriateness of care provided in MCC.
METHODS: An anonymous online survey, with convenience sampling of adults self-reporting prescribed medicinal cannabis in the preceding 12 months. Outcomes included participant characteristics, indications and patterns of cannabis use, consumer satisfaction.
RESULTS: Most participants (1899/2394, 79.3%) accessed treatment from MCC. Compared to generalist settings, MCC participants were younger (3.5 years, 95%CI: -4.7, -2.2), less likely to be prescribed oral products (OR = 0.4, 0.4-0.5), and had higher rates of employment (OR = 2.1, 1.8-2.5) and cannabis use disorder (OR = 1.5, 1.2-1.8). MCC participants were less likely to seek treatment for chronic pain (OR = 0.7, 0.6-0.8), but more likely for mental health conditions (OR = 1.6, 1.3-2.0). MCC participants had lower satisfaction levels regarding consultation duration (OR = 0.8, 0.7-0.9), information about potential harms and benefits (OR = 0.7, 0.6-0.9), use of other treatment approaches (OR = 0.5, 0.4-0.6) and treatment costs (OR = 0.6, 0.5-0.7).
CONCLUSION: We identified differences in the profile of patients, type of treatment provided between service settings, and there were higher levels of satisfaction amongst consumers accessing treatment in GHS settings. Further research is required to examine other dimensions of quality and appropriateness of care provided in MCC.